EU Committee Recommended Approval for VaxRabeo Vaccine
The EMA recommended authorization for a new rabies vaccine intended for both pre-exposure and postexposure prophylaxis.
Updated on Sept. 22, 2026 in Allergies
Live Poll
Should regulatory panels approve new vaccines for use across all age groups?
The Committee for Medicinal Products for Human Use has recommended marketing authorization for VaxRabeo, a purified inactivated rabies vaccine. The treatment is intended for all age groups to prevent rabies, a disease with a near 100% case fatality rate once symptoms appear.
Why it matters
As dog bites are responsible for 99% of human rabies cases, this vaccine aims to provide a reliable protective antibody response. The drug induces neutralizing antibodies against the surface glycoprotein of the virus to bolster immunity.
Clinical trials for VaxRabeo observed common side effects including injection-site pain and myalgia in both children and adults. In the 12-23 month age group, irritability and crying were also reported following administration.
The players
European Medicines Agency
This is a decentralised agency of the European Union responsible for the scientific evaluation and supervision of medicines.
Committee for Medicinal Products for Human Use
This committee is the branch of the European Medicines Agency responsible for preparing opinions on questions relating to human medicines.
European Commission
This institution acts as the executive branch of the European Union and will issue the final marketing authorization for the vaccine.
The details
Administered as a suspension created from a powder and solvent, the vaccine functions by stimulating the body to create neutralizing antibodies. The European Commission is expected to finalize the marketing authorization process in approximately 67 days.
Timeline
September 2026: The Committee for Medicinal Products for Human Use adopted the positive opinion.
67 days after September 2026: The European Commission is expected to issue a final marketing authorization decision.
Health Landscape
This development follows strict regulatory requirements that mandate the publication of the Summary of Product Characteristics in all official European Union languages. This ensures that standardized safety and efficacy data remains accessible across the region's diverse healthcare systems.
Once authorized, this vaccine will provide a new option for pre-exposure and postexposure prophylaxis across all age groups. Patients should consult with healthcare providers regarding its availability and suitability for their specific health needs.
The takeaway
Rabies remains a highly lethal disease that necessitates effective prophylactic intervention following high-risk exposure incidents. Consistent vaccination remains the most critical strategy for preventing fatalities in human populations exposed to rabies.
What happens next
The European Commission is expected to issue a final decision regarding marketing authorization approximately 67 days after the September 2026 committee recommendation.
Further reading
For more information on medical preventative measures, visit the Allergies section.
Source note: This article includes information reported by Medscape.
Live Poll
Should regulatory panels approve new vaccines for use across all age groups?
